4
Changes in Ownership
IONIS PHARMACEUTICALS INC Filed Acc 0000874015-24-000059
EVP, Chf Clinical Develop Ofcr sold 8,000 shares at $53.50 ($427,999)
- EVP, Chf Clinical Develop Ofcr acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Schneider Eugene · EVP, Chf Clinical Develop Ofcr
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-01-12 | Exercise or conversion : show line 1 in the form 10b5-1 | +8,000 | $32.60 | $260,800 | 46,170 | D |
| 2024-01-12 | Sale : show line 2 in the form 10b5-1 | −8,000 | $53.50 | $427,999 | 38,170 | D |
| Open-market sales · 8,000 sh · avg $53.50 · $427,999 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2024-01-12 | Exercise or conversion : show line 3 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −8,000 | $32.60 | 2032-01-02 | 8,000 | 24,265 | D |
| 2024-01-15 | Grant or award : show line 4 in the form 10b5-1 Performance Restricted Stock Units | +17,000 | $0.00 | 17,000 | 43,437 | D | |
| 2024-01-15 | Grant or award : show line 5 in the form 10b5-1 Restricted Stock Unit | +20,400 | $0.00 | 20,400 | 60,470 | D |
Loading xslF345X05/edgardoc.xml…